~~<i id='D32A6D1AF4'><strike id='D32A6D1AF4'><tt id='D32A6D1AF4'><pre id='D32A6D1AF4'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：explore 2025-09-30 20:14:19 Page View：418

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Nonprofit, backed by Microsoft, to certify AI tools in health care
Next article： Continuity nursing helped my family in our darkest PICU moments

comprehensive

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Boston Scientific acquires urology company Axonics for $3.7 billion

BostonScientificisgrowingitsurologyportfoliowiththeAxonicsacquisition.StevenSenne/APBostonScientific

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletter